Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

9.8%

8 terminated/withdrawn out of 82 trials

Success Rate

78.9%

-7.6% vs industry average

Late-Stage Pipeline

49%

40 trials in Phase 3/4

Results Transparency

1 of 30 completed trials have results

Key Signals

1 with results7 withdrawn

Enrollment Performance

Analytics

Phase 3

39(49.4%)

Phase 2

18(22.8%)

Phase 1

17(21.5%)

Early Phase 1

2(2.5%)

N/A

2(2.5%)

Phase 4

1(1.3%)

79Total

Phase 3(39)

Phase 2(18)

Phase 1(17)

Early Phase 1(2)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (82)

Showing 20 of 82 trials

NCT05337540Not ApplicableCompleted

A Study to Evaluate the Efficacy, Safety and Tolerability of EVI-01 Intra-Articular Injection in Osteoarthritis of the Knee

Role: collaborator

NCT03252535Phase 2Completed

Dose-response Evaluation of the Cellavita HD Product in Patients With Huntington's Disease

Role: lead

NCT06817096Phase 3Not Yet Recruiting

Efficacy and Safety of Nitazoxanide 600 Mg in the Outpatient Treatment of COVID-19 and Influenza

Role: lead

NCT05603403Phase 4Completed

Efficacy And Safety Of Probiatop In The Treatment Of Digestive Symptoms

Role: lead

NCT06303635Not Yet Recruiting

Safety of UFRJvac, Trivalent COVID-19 Vaccine

Role: lead

NCT06089122Phase 3Unknown

Efficacy, Safety, and Pharmacokinetics of Shu Yang IVIG

Role: lead

NCT06150833Phase 3Unknown

Efficacy and Safety and Pharmacokinetics of Boya IVIG

Role: lead

NCT06097780Phase 3Not Yet Recruiting

Efficacy and Safety of NestaCell® in Huntington's Disease

Role: lead

NCT04329572Early Phase 1Suspended

Efficacy and Safety of Hydroxychloroquine and Azithromycin for Patients With Moderate to Severe COVID-19

Role: lead

NCT04348474Early Phase 1Suspended

Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Ambulatory Patients With Mild COVID-19

Role: lead

NCT00717652Phase 2Suspended

Efficiency And Safety Of Association Arbutin, Triamcinolone And Tretinoin In Treatment Of Melasma

Role: lead

NCT03572647Phase 1Completed

Pharmacokinetics and Pharmacodynamics Assessment of Drug Eritromax Compared to Eprex in Healthy Subjects.

Role: lead

NCT00701623Phase 2Withdrawn

Sodic Heparin Effectiveness of the Treatment of Burns

Role: lead

NCT01244256Phase 2Suspended

Efficacy and Comparative of the Association Beclomethasone Clotrimzaol + Gentamicin in Patients With Acne Contaminated

Role: lead

NCT01228643Phase 3Withdrawn

Effectiveness of Pancreatic Enzymes in Patients Pancreatic Insufficient: Comparison of Two Drugs

Role: lead

NCT00701974Phase 2Suspended

Non-inferiority Clinic of Kollagenase® Compared Iruxol® in Treatment of Cutaneous Ulcers

Role: lead

NCT01228656Phase 2Suspended

Effectiveness of Association Mometasone Furoate 0.1% and Salicylic Acid 5% Compared With Mometasone Furoate

Role: lead

NCT01086982Phase 1Suspended

Pharmacodynamics Of Product Octreotide Acetate Lar 30 Mg Compared To Product Sandostatin LAR ®

Role: lead

NCT01229072Phase 2Suspended

Safe Use of Heparin Sodium in Patients With Chronic Renal Failure.

Role: lead

NCT01125761Phase 3Withdrawn

Efficacy and Safety of the Association Drugs in Patients With Allergic Dermatitis

Role: lead